Identification
Personal identification
- Full name
- Nuno André Carvalho da Fonseca
Citation names
- Fonseca, Nuno A.
Author identifiers
- Ciência ID
- C01F-8090-3B04
- ORCID iD
- 0000-0003-4970-7288
- Google Scholar ID
- https://scholar.google.pt/citations?user=AQdApQkAAAAJ&hl=pt-PT
- Researcher Id
- AAF-1747-2020
- Scopus Author Id
- https://www.scopus.com/authid/detail.uri?authorId=56343290600
Email addresses
- nuno.fonseca@cnc.uc.pt (Professional)
Telephones
- Telephone
-
- 239820190 (Professional)
Addresses
- Rua Larga, Faculdade de Medicina, Pólo 1, 1º Andar, 3004-504, Coimbra, Coimbra, Portugal (Professional)
Websites
- https://cibb.uc.pt/ (Scholar)
Knowledge fields
- Medical and Health Sciences - Health Sciences
- Engineering and Technology - Nano-technology
- Medical and Health Sciences - Medical Biotechnology - Health-Related Biotechnology
- Natural sciences - Biological Sciences - Cell Biology
- Medical and Health Sciences - Medical Biotechnology - Technologies Involving the Manipulation of Cells, Tissues, Organs or the Whole Organism
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
Portuguese (Mother tongue) | |||||
English | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) |
French | Beginner (A1) | Elementary (A2) | Beginner (A1) | Beginner (A1) | Beginner (A1) |
Education
Degree | Classification | |
---|---|---|
2010/02 - 2015/07
Concluded
|
Doutoramento em Ciências Farmacêuticas, especialidade de Tecnologia Farmacêutica (Doutoramento)
Universidade de Coimbra Faculdade de Farmácia, Portugal
"Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer." (THESIS/DISSERTATION)
|
Aprovado com distinção e louvor |
2004/09 - 2009/07
Concluded
|
Mestrado Integrado em Ciências Farmacêuticas (Mestrado integrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
16 |
Affiliation
Science
Category Host institution |
Employer | |
---|---|---|
2020/07/01 - 2021/03/31 | Research Assistant (Research) | Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal |
2019/02/01 - 2020/06/30 | Postdoc (Research) | Universidade de Coimbra, Portugal |
Centre for Innovative Biomedicine and Biotechnology, Portugal | ||
2016/11/01 - 2019/01/31 | Postdoc (Research) | CNC.IBILI, Portugal |
CNC.IBILI, Portugal | ||
2010/02/01 - 2014/01/31 | Researcher (Research) | CNC.IBILI, Portugal |
Others
Category Host institution |
Employer | |
---|---|---|
2021/04/01 - Current | Formulation Scientist | Bluepharma, Portugal |
2014/02 - 2016/10 | Associate Director of Research & Development | TREAT U, SA, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
2016 - 2019 | Towards a single therapy with a synergistic drug combination against triple negative breast cancer and neuroblastoma by nucleolin-mediated
multicellular targeting
Post-doc
|
Fundação para Ciência e Tecnologia
Ongoing
|
2010/02 - 2014/01 | Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer
SFRH/BD/64243/2009
PhD Student Fellow
|
Fundação para Ciência Tecnologia |
2012 - 2013 | ANTI-STEM CELLS - Targeted delivery of drug combinations towards cancer stem cells
Researcher
CNC.IBILI, Portugal
|
InovC - Universidade de Coimbra
Concluded
|
Outputs
Publications
Book chapter |
|
Conference abstract |
|
Conference paper |
|
Conference poster |
|
Journal article |
|
Thesis / Dissertation |
|
Intellectual property
Patent |
|
Provisional application for patent |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2019/07 | Nucleolin-mediated Drug Delivery Blocks Growth Of Biphasic Mesothelioma Through Disruption Of Its Molecular Signature | 2019 Controlled Release Society Annual Meeting; 2019 July 20-24
Controlled Release Society (Valencia, Spain)
|
2018/10 | Cancer | “Diálogos com Cientistas - Desafios na Saúde: Doenças do Séc. XXI”
IEC – Instituto de Educação e Cidadania. (Aveiro, Portugal)
|
2018/07 | Targeting solid tumors with lipid-based nanoparticles | 2018 Seminar Series, BEB -PhD Programme
CNC.IBILI (Coimbra, Portugal)
|
2018/01/16 | Tumor intracellular bioavailability of doxorubicin determines therapeutic efficacy of GLP grade nanoparticle targeted to nucleolin independently of systemic exposure. | XII Spanish-Portuguese Conference on Controlled Drug Delivery
Spanish-Portuguese Local Chapter of the Controlled Release Society (Coimbra, Portugal)
|
2017/05 | Addressing the tumor microenvironment with targeted nanotechnologies | Evaluation Event of Everis Awards 2017
Everis Foundation (Madrid, Spain)
|
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2018/09 - Current | Tumor delivery of synergistic drug combinations
Co-supervisor
|
Pharmaceutical Biotechnology Masters (Master)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
Event participation
Activity description Type of event |
Event name Institution / Organization |
|
---|---|---|
2014 - 2014 | Adobe Illustrator for Sciences.
Workshop
|
CNC.IBILI, Portugal
|
2014 - 2014 | How to write a competitive proposal for HORIZON 2020.
Workshop
|
Associação para a Inovação e Desenvolvimento em Ciência e Tecnologia, Portugal
|
2014 - 2014 | Animal experimentation certification - Category B
Other
|
Laboratory animals course.
CNC.IBILI, Portugal
|
2014 - 2014 | EACR-23: From Basic Research to Personalized Cancer Treatment. Munich, Germany
Congress
|
European Association For Cancer Research, United Kingdom
|
2012 - 2012 | LabLinks: Tumor Microenvironment. United Kingdom.
Symposium
|
King's College London, United Kingdom
|
2012 - 2012 | Workshop on Microarray Applications in Biomedicine
Workshop
|
Biocant Associação de Transferência de Tecnologia, Portugal
|
2011 - 2011 | Champalimaud Cancer Research Symposium in tribute to the work of Judah Folkman
Symposium
|
Fundação Champalimaud, Portugal
|
2010 - 2010 | Survival or death as a matter of fat.
Congress
|
CNC.IBILI, Portugal
|
Course / Discipline taught
Academic session | Degree Subject (Type) | Institution / Organization | |
---|---|---|---|
2020/12/05 - 2020/12/05 | TARGETED DELIVERY OF SYNERGISTIC DRUG COMBINATIONS: Tackling cancer stem cells in human breast cancer | Masters in Pharmaceutical Biotechnology (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2019/05 - 2019/05 | Nucleolin-targeted delivery: from enhanced tumor accumulation to cancer stem cell targeting | (Doutoramento) | CNC.IBILI, Portugal |
2019 - 2019 | TARGETED DELIVERY OF SYNERGISTIC DRUG COMBINATIONS: Tackling cancer stem cells in human breast cancer | Pharmaceutical Biotechnology Masters 2019-2020 (Mestrado) (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2018 - 2018 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Pharmaceutical Biotechnology Masters 2018-2019 (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2018 - 2018 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Principles and Practice in Drug Development MIT-PORTUGAL Program 2017/2018, (Doutoramento) | CNC.IBILI, Portugal |
2017 - 2017 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Pharmaceutical Biotechnology Masters 2017/2018 (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2017 - 2017 | Tackling breast cancer stem cells through targeted delivery of synergistic combinations. | Principles and Practice in Drug Development MIT-PORTUGAL Program 2016-2017 (Doutoramento) | CNC.IBILI, Portugal |
2016 - 2016 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Pharmaceutical Biotechnology Masters 2016/2017 (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2016 - 2016 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Principles and Practice in Drug Development MIT-PORTUGAL Program 2015/2016 (Doutoramento) | CNC.IBILI, Portugal |
2016 - 2016 | Targeted delivery of synergstic drug combinations: tackling cancer stem cells in human breast cancer. | Advanced Therapeutics 2016, BEB PhD Program (Doutoramento) | CNC.IBILI, Portugal |
2015 - 2015 | Targeted intracellular delivery of synergistic combinations: tackling drug resistance in human breast cancer. | Principles and Practice in Drug Development MIT-PORTUGAL Program 2014/2015 (Doutoramento) | CNC.IBILI, Portugal |
2014 - 2014 | Nanotechnology mediated targeting of cancer stem cells. | Pharmaceutical Biotechnology Masters 2014/2015 (Mestrado) | Universidade de Coimbra Faculdade de Farmácia, Portugal |
2012 - 2012 | FACS as a tool for drug delivery, gene silencing and cell viability assessment. | CNC Cores – BEB PhD Programme, (Doutoramento) | CNC.IBILI, Portugal |
2011 - 2011 | Drug Delivery, Gene Silencing and Viability Impact Assessment by Flow Cytometry | CNC Cores – BEB PhD Programme (Doutoramento) | CNC.IBILI, Portugal |
Evaluation committee
Activity description Role |
Institution / Organization | Funding entity | |
---|---|---|---|
2017 - 2018 | Participation in MSs and Post-Doc fellowship evaluation panels under the project "HealthyAging2020" - CENTRO-01-0145-FEDER-000012
Member
|
Universidade de Coimbra, Portugal | Comissão de Coordenação e Desenvolvimento Regional do Centro |
2016 - 2017 | Participation in MSc or Post-Doc fellowship evaluation panels under the project "ODD4PEGASEMP - PEGASEMP™ as an orphan drug
for the treatment of rare diseases: a curative therapy for mesothelioma" - CENTRO-01-0247-FEDER-017646 (funded by the European
Fund for Regional Development (FEDER), through the Regional Operational Program for the Center Region of Portugal (Centro
2020))
Member
|
Universidade de Coimbra, Portugal | Comissão de Coordenação e Desenvolvimento Regional do Centro |
Mentoring / Tutoring
Topic | Student name | |
---|---|---|
2017/06 - 2018/01 | ODD4PEGASEMP - PEGASEMP™ as an orphan drug for the treatment of rare diseases: a curative therapy for mesothelioma (CENTRO-01-0247-FEDER-017646) | Sónia Pinho |
2017/01 - 2018/01 | ODD4PEGASEMP - PEGASEMP™ as an orphan drug for the treatment of rare diseases: a curative therapy for mesothelioma (CENTRO-01-0247-FEDER-017646) | Ana Rafaela Oliveira |
2017/09 - 2017/09 | Module 8 - Minimally invasive procedures without anaesthesia in mouse and rats (administration of substances) | n/a |
2012 - 2016 | Meeting the needs of breast cancer: a nucleolin's perspective | Gregório, Ana Cristina Leal |
2012 - 2016 | Targeting Nucleolin in Lung Cancer: Towards a Personalized Therapy | Fernandes, Ângela Filipa Valério |
2014 - 2015 | Impacto de uma nova estratégia nanoterapêutica em células estaminais tumorais de cancro do pulmão | Araújo, Rute Silva |
2013 - 2014 | Caracterização físico-química e biológica da nanopartículas para o tratamento de leucemias | Cecílio, Susana Cristina Cristo |
2012 - 2013 | Desenvolvimento de nanopartículas para o tratamento do cancro | Monteiro, Vanessa Filipa Florêncio |
Distinctions
Award
2013 | The poster entitled "Assessing the potential of nucleolin-targeted strategies against Lung Cancer resistant to anti-VEGF therapies" won Best Poster Presentation in the category of Translational & Clinical Research |
Other distinction
2018 | FDA granted the orphan designation for PEGASEMP™(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified
with a 31 aminoacid peptide targeting nucleolin).
US Food and Drug Administration, United States
|
2017 | European Commission granted TREAT U, S.A., Portugal, the orphan designation for doxorubicin hydrochloride in a lipid-based
pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin for the treatment of malignant mesothelioma.
European Medicines Agency, United Kingdom
|
2014 | Scale-up under GMP of a targeted liposomal formulation.
TREAT U, SA, Portugal
|